Previous 10 | Next 10 |
AVEO Oncology ( AVEO ) recently reported their Q1 and provided an update on their operations, which triggered a surge in the share price. The company has submitted their NDA to the FDA for Tivozanib (FOTIVDA) in relapsed or refractory renal cell carcinoma “R/R RCC” and was ready ...
- Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking a...
The following slide deck was published by AVEO Pharmaceuticals, Inc. in conjunction with this Read more ...
AVEO Oncology ( AVEO -11.7% ) is under pressure, although up from the intraday low of $7.05, on the heels of its report of overall survival (OS) data from its Phase 3 TIVO-3 study comparing tivozanib to Bayer's ( OTCPK:BAYRY -0.6% ) Nexavar (sorafenib) in renal cell carcinoma patient...
ARCA biopharma (NASDAQ: ABIO ) -28% . More news on: ARCA biopharma, Inc., ToughBuilt Industries, Inc., Canopy Growth Corporation, Stocks on the move, , Read more ...
AVEO Oncology (NASDAQ: AVEO ) announces that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA (tivozanib), in combination with IMFINZI (durvalumab), AstraZeneca’s (NYSE: AZN ) human monoclonal antibody, in patients with hepatocellular carcinoma (HCC) who have not received ...
AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combinati...
- Final OS Hazard Ratio Improves to 0.97 - - Company to Host Conference Call Today at 8:30 am Eastern Time - AVEO Oncology (NASDAQ: AVEO) today announced the presentation of results from the final analysis of overall survival (OS) in its pivotal Phase 3 TIVO-3 trial comparing tivo...
AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and commu...
Gainers: Hertz Global (NYSE: HTZ ) +104% . More news on: Hertz Global Holdings, Inc., Euroseas Ltd., Mersana Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...